News & Videos - EDITAS MEDICINE INC. - Page 3

EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Achieved proof of concept and identified a responder population In view of the small population, the Company will pause enrollment in the BRILLIANCE trial and seek to identify a collaboration partner to continue development of EDIT-101 Company to host a webinar today at 8:00 a.m. ET CAMBRIDGE, Mass.,...

Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clinical update on the Phase 1/2 BRILLIANCE trial for EDIT-101 this month CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome...

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2022. To access the conference call: U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins. Participants...

Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach Treated eyes showed morphological and functional photoreceptor preservation EDIT-103 advancing towards IND-enabling studies CAMBRIDGE, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced ex vivo and in vivo preclinical data supporting its...

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference Format: Fireside Chat Date: Wednesday, September 7, 2022 Time: 1:55 p.m. ET Location: Everett, MA Morgan Stanley 20 th Annual Global Healthcare Conference Format: Fireside Chat Date: Monday, September 12, 2022 Time: 10:30 a.m. ET Location:...

Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease; first clinical use of Editas-engineered AsCas12a enzyme FDA removed partial clinical hold for RUBY trial of EDIT-301 Continued screening and enrolling new adult and pediatric patients for EDIT-101 Phase 1/2 BRILLIANCE study for LCA10, with clinical data update expected 2H 2022 On track to initiate...

Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301 First clinical use of Editas-engineered AsCas12a enzyme Initial clinical data from the RUBY trial expected by year-end CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the dosing and confirmed successful neutrophil and platelet engraftment of the first patient...

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corporate updates for the second quarter of 2022. To access the conference call: U.S. callers should dial 1-877-407-0989, and international callers should dial +1-201-389-0921 approximately five minutes before the call begins....

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Baisong Mei, M.D., Ph.D. In connection with Dr. Mei’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Mei as an inducement material to Dr. Mei entering into employment with Editas Medicine in accordance with Nasdaq Listing...

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company’s Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei will lead clinical research and drug development for the Company’s pipeline of experimental medicines across all therapeutic indications, including hematology, oncology, and ophthalmology. “We are thrilled to...

TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta...

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed President and Chief Executive Officer, Gilmore O’Neill, M.B., M.M.Sc. As previously announced, Dr. O’Neill joined the Company on June 1, 2022, in his new role. In connection with Dr. Gilmore’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr....

SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persistence in an ovarian cancer mouse model CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present data later today on its SLEEK (SeLection by Essential- gene Exon Knock-in) gene editing technology during the New Gene...

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for the treatment of beta thalassemia. The FDA previously granted Rare Pediatric Disease designation to EDIT-301 for the treatment of beta thalassemia and sickle cell disease. “Beta thalassemia is a devastating disease...

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels Treated eyes showed morphological and functional photoreceptor preservation EDIT-103 advancing towards IND-enabling studies CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced ex vivo and in vivo preclinical data for its experimental medicine EDIT-103 for the...

Appointed Gilmore O’Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman First pediatric patient dosed in Phase 1/2 BRILLIANCE trial of EDIT-101 for LCA10; clinical data update expected in 2H 2022 On track to dose first SCD patient in 1H 2022 and first TDT patient by year-end with EDIT-301; initial SCD data expected by year-end Preclinical data demonstrated that edited iNK cells increased persistence, enhanced anti-tumor activity, and extended survival,...

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, including three oral presentations, at the 25 th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held in Washington, D.C., and virtually, May 16 – 19, 2022. The Company is presenting data on its pipeline and platform technologies to support ongoing development programs....

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of 2022. To access the conference call: U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins. Participants should ask...

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia. The FDA previously granted Rare Pediatric Disease designation to EDIT-301 for the treatment of sickle cell disease. “Beta thalassemia is a devastating disease that leads to...

James C. Mullen to Serve as Executive Chairman CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has appointed Dr. Gilmore O’Neill, M.B., M.M.Sc., as President and Chief Executive Officer. James C. Mullen will serve as Executive Chairman of the Company’s Board of Directors. These changes are effective June 1, 2022. Dr. O’Neill brings to Editas nearly 20 years of experience...